证券代码：920300 证券简称：辰光医疗 公告编号：2026-014 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 | 单位：元 | | --- | | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 89,939,697.09 | 119,001,736.41 | -24.42% | | 利润总额 | -51,898,763.58 | -68,663,974.94 | 24.42% | | 归属于上市公司股东的净 | -60,736,016.14 | -60,898,635.50 | 0.27% | | 利润 | | | | | 归属于上市公司股东的扣 | -63,928,237.72 | -68,386,717. ...

Core Insights - The MRI superconducting magnet industry in China is experiencing significant growth due to advancements in domestic production capabilities and technology, particularly in helium-free technology and high-field magnet performance optimization [1][4][6] - By 2025, China's MRI superconducting magnet production capacity is expected to reach 1,400 units, with a production volume of 900 units and a market size of 3.032 billion yuan [1][5] - The global MRI superconducting magnet market is projected to grow from $1.278 billion in 2020 to $1.582 billion by 2025, indicating strong demand driven by both developed and developing markets [4][6] Industry Definition - Superconducting magnets are electromagnetic devices that utilize superconducting materials to generate strong magnetic fields without energy loss, essential for MRI imaging [2][3] - MRI superconducting magnets are critical components of MRI devices, providing the necessary magnetic field for imaging [2] Industry Development History - The development of China's MRI superconducting magnet industry can be divided into three phases: technology introduction and initial exploration (1980s-1990s), independent research and industrialization (early 2000s-2010s), and high-end breakthroughs and domestic substitution (2010s-present) [4] Current Industry Status - The domestic MRI superconducting magnet industry has seen a steady demand, with production capacity and quality improving significantly due to local technological advancements and increased domestic supply chain capabilities [4][5] - By 2026, the industry is expected to see further increases in production capacity to 1,500 units and a market size of 3.235 billion yuan [1][5] Industry Supply Chain - The supply chain for the MRI superconducting magnet industry includes upstream materials such as niobium-titanium (NbTi), niobium-tin (Nb3Sn), and liquid helium, with the midstream focusing on magnet production and the downstream involving MRI machine manufacturing [6] Industry Development Environment - Recent government policies have supported the high-end medical equipment industry, emphasizing the importance of domestic production capabilities in key components like superconducting magnets [6][8] Competitive Landscape - The MRI superconducting magnet market is dominated by major international players like Siemens, GE, and Philips, while domestic companies are gaining market share through competitive pricing and localized services [8][10] - Key domestic companies include Ningbo Jiexin Superconducting Technology Co., Weifang New Power Superconducting Technology Co., Shanghai United Imaging Healthcare Co., and Western Superconducting Technologies Co. [8][10] Industry Trends - The domestic market is expected to accelerate the process of domestic substitution, with a significant increase in the localization rate of superconducting magnets [12][14] - The industry is likely to see a concentration of market resources towards companies with technological advantages and global reach, while smaller firms may focus on niche markets [15]

Trading Information Summary - On February 4, 2026, Chen Guang Medical (920300) closed at 14.87 yuan, up 0.95%, with a turnover rate of 2.01% and a trading volume of 13,400 shares, amounting to a transaction value of 19.9093 million yuan [1]. - On the same day, the net inflow of main funds was 283,700 yuan, accounting for 1.42% of the total transaction value; the net inflow of speculative funds was 456,500 yuan, accounting for 2.29%; while retail investors had a net outflow of 1.2111 million yuan, accounting for 6.08% [1][3]. Shareholder Changes - On February 4, 2026, Chen Guang Medical announced that its shareholder Tian Lifeng reduced her holdings by a total of 70,000 shares from January 10 to January 14, 2026, which accounted for 0.0815% of the company's total share capital. During this period, the stock price increased by 7.42%, closing at 17.38 yuan on January 14 [1]. - Tian Lifeng cumulatively reduced her holdings by 226,501 shares between November 13, 2025, and January 14, 2026, representing 0.2638% of the total share capital, with a reduction price range of 14.99 to 18.01 yuan per share, totaling 3.875 million yuan. After this reduction, her shareholding decreased to 4,678,693 shares, representing 5.4500% of the total share capital. The reduction plan has not been completed, and the reduction period has expired, consistent with previous disclosures [1][3].

证券代码：920300 证券简称：辰光医疗 公告编号：2026-013 上海辰光医疗科技股份有限公司 持股 5%以上股东减持股份结果公告 本公司及董事会全体成员及相关股东保证公告内容不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 一、 减持主体减持前基本情况 | 股东名称 | 股东身份 | | 持股数量 | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | | | | （股） | （%） | | | 田丽芬 | 持股 | 5%以上 | 4,905,194 | 5.7139% | 北交所上市前取得 | | | 股东 | | | | | □减持计划实施完毕 √减持时间区间届满 | 股 | | 减持数 | | | | | | | 减持 | | 当前持 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 东 | 减持数量 | 量占总 | 减持 | | 减持 | | 减持价格区 | 已减持总金 | 计划 | 当 ...

Group 1 - The core point of the article is that Chen Guang Medical announced a share reduction by a major shareholder, Tian Lifeng, which will take place between November 13, 2025, and January 14, 2026, involving approximately 230,000 shares [1] - The reduction amount is approximately 3.88 million yuan, with a share price range of 14.99 yuan to 18.01 yuan per share [1] - After the reduction, Tian Lifeng will hold about 4.68 million shares, representing a 5.45% ownership stake in the company [1]

Group 1 - The core viewpoint is that Chuangguang Medical (920300) is expected to report a net loss of between 53 million to 66 million yuan for the year 2025, indicating a narrowing of losses compared to the previous year [1][3]. - The company's revenue decline is primarily attributed to intensified competition in the magnetic resonance imaging (MRI) equipment industry and the lack of sales for the 7.0T MRI system, which is a niche product for research purposes [1][3]. - On January 29, 2026, Chuangguang Medical's stock closed at 14.99 yuan, down 1.51%, with a turnover rate of 2.55% and a trading volume of 16,900 shares, amounting to a transaction value of 25.583 million yuan [1]. Group 2 - On January 29, 2026, the net outflow of main funds was 1.2801 million yuan, accounting for 5.0% of the total transaction value [1][3]. - The net outflow of retail funds was 0.2133 million yuan, representing 0.83% of the total transaction value [1]. - The overall performance forecast indicates that the company is facing challenges in maintaining revenue levels due to market conditions [1][3].

证券代码：920300 证券简称：辰光医疗 公告编号：2026-012 上海辰光医疗科技股份有限公司 2025 年年度业绩预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 二、本期业绩重大变化的主要原因 2025 年度公司营业收入有所下降，公司营收增长仍受磁共振整机行业竞 争格局影响。2025 年中国磁共振系统市场保持持续竞争态势，特别是头部企业 针对集采"带量采购，以量换价"的政策，医学影像设备行业中标价同比大幅 下降，因此公司的 1.5T 磁共振系统销售收入受到影响。此外公司 7.0T 磁共振 系统，由于属于科研用小众产品、单价高，市场销售存在不稳定性，2025 年没 有实现销售，对公司营业收入产生较大影响。 三、风险提示 一、本期业绩预告情况 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 √年度净利润为负值 单位：万元 | 项目 | 本报告期 | 上年同期 | | 变动比例% | | --- | --- | --- | --- ...

Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

证券代码：920300 证券简称：辰光医疗 公告编号：2026-010 （一）会议召开情况 1.会议召开时间：2026 年 1 月 20 日 下午 15:00 2.会议召开地点：上海市青浦区华青路 1269 号 3.会议召开方式：本次会议采用现场投票和网络投票相结合方式召开 4.会议召集人：公司第五届董事会 5.会议主持人：董事长 王杰先生 上海辰光医疗科技股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）审议通过《关于公司拟向招商银行股份有限公司上海分行申请并使用授信 额度的议案》 1.议案表决结果： 6.召开情况合法合规的说明： 本次股东会会议召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。会议召开不需要相关部门批准或履行必要程序。 （二）会议出席情况 出席和授权出席本次股东会的股东共 6 人，持有表决权的股份总数 25,754,102 股，占公司有表决权股份总数的 30.0000%。 其中通过网 ...

之 法律意见书 上海市海华永泰律师事务所 关于上海辰光医疗科技股份有限公司 2026 年第一次临时股东会 上海总部：上海市浦东新区陆家嘴环路 1366 号富士康大厦 12 层 电话：8621—58773177 传真：8621—58773268 二零二六年一月 上海市海华永泰律师事务所 关于上海辰光医疗科技股份有限公司 2026年第一次临时股东会 之 法律意见书 致:上海辰光医疗科技股份有限公司 上海市海华永泰律师事务所（以下简称"本所"）接受上海辰光医疗科技股 份有限公司（以下简称"公司"）的委托，指派本所王依来律师（以下简称"经 办律师"）出席了公司 2026年第一次临时股东会会议（以下简称"本次股东会"), 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》(以下简称"《证券法》")、中国证券监督管理委员会发布的《上市 公司股东会规则》(以下简称"《股东会规则》")、《上海辰光医疗科技股份有 限公司章程》（以下简称"《公司章程》"）和《上海辰光医疗科技股份有限公 司股东会议事规则》（以下简称"《股东会议事规则》"）等规定,对本次股东 会的相关事宜依法见证，并出具本法律意见书 ...